Demographics
| Demographic | Belgium | United States | P | ||
| ALS | HV | ALS | HV | ||
| Age (y) | 58.9 ± 6.7 | 52.1 ± 15.2 | 53.4 ± 9.8 | 54.6 ± 9.6 | 0.72 |
| Sex (n) | 0.49 | ||||
| Men | 5 | 3 | 5 | 4 | |
| Women | 2 | 5 | 2 | 3 | |
| TSPO binding affinity | 0.12 | ||||
| High-affinity binder | 3 | 0 | 4 | 5 | |
| Medium-affinity binder | 3 | 7 | 3 | 2 | |
| Low-affinity binder | 1 | 1 | 0 | 0 | |
| ALSFRS-R | 43.4 ± 1.9 | 38.1 ± 4.4 | 0.02 | ||
| VC (% predicted) | Forced VC: 106.7 ± 25.0 | Slow VC: 84.3 ± 16.1 | 0.09 | ||
| Disease duration (mo) | 6.3 ± 2.8 | 14.7 ± 4.7 | 0.003 | ||
ALSFRA-R = revised ALS functional rating scale; VC = vital capacity.
Data are mean ± SD. ANOVA was performed for continuous variables, and χ2 test was performed for categoric variables.